KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Sabra Health Care REIT (SBRA) Shares Outstanding (Weighted Average) (2016 - 2022)

Sabra Health Care REIT (SBRA) has 15 years of Shares Outstanding (Weighted Average) data on record, last reported at $241.3 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.35% year-over-year to $241.3 million; the TTM value through Dec 2025 reached $241.3 million, up 3.35%, while the annual FY2025 figure was $241.3 million, 3.35% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $241.3 million in Q4 2025 per SBRA's latest filing, up from $239.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $241.3 million in Q4 2025 and bottomed at $211.5 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $230.1 million, with a median of $231.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 9.18% in 2022, then increased 0.1% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $219.1 million in 2021, then rose by 5.42% to $230.9 million in 2022, then increased by 0.11% to $231.2 million in 2023, then grew by 0.99% to $233.5 million in 2024, then grew by 3.35% to $241.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $241.3 million in Q4 2025, $239.9 million in Q3 2025, and $237.9 million in Q2 2025.